Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. by Stone, Gregg W et al.
Stone, GW; Ware, JH; Bertrand, ME; Lincoff, AM; Moses, JW;
Ohman, EM; White, HD; Feit, F; Colombo, A; McLaurin, BT; Cox,
DA; Manoukian, SV; Fahy, M; Clayton, TC; Mehran, R; Pocock,
SJ (2007) Antithrombotic strategies in patients with acute coronary
syndromes undergoing early invasive management - One-year results
from the ACUITY trial. JAMA, 298 (21). pp. 2497-2506. ISSN
0098-7484 DOI: https://doi.org/10.1001/jama.298.21.2497
Downloaded from: http://researchonline.lshtm.ac.uk/7861/
DOI: 10.1001/jama.298.21.2497
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
ORIGINAL CONTRIBUTION
Antithrombotic Strategies in Patients
With Acute Coronary Syndromes
Undergoing Early Invasive Management
One-Year Results From the ACUITY Trial
Gregg W. Stone, MD
James H. Ware, PhD
Michel E. Bertrand, MD
A. Michael Lincoff, MD
Jeffrey W. Moses, MD
E. Magnus Ohman, MD
Harvey D. White, MD
Frederick Feit, MD
Antonio Colombo, MD
Brent T. McLaurin, MD
David A. Cox, MD
Steven V. Manoukian, MD
Martin Fahy, MSc
Tim C. Clayton, MSc
Roxana Mehran, MD
Stuart J. Pocock, PhD
for the ACUITY Investigators
EARLY ANGIOGRAPHY FOLLOWEDby interventional or surgicalrevascularization when appro-priate has been shown to
result in reduced rates of death, myo-
cardial infarction (MI), refractory
ischemia, and rehospitalization in
patients with acute coronary syn-
dromes (ACS; unstable angina or
non–ST-segment elevation MI).1,2
Because both MI and hemorrhagic
complications have been associated
with early and late mortality in
patients with ACS and in those
undergoing percutaneous coro-
nary intervention (PCI),3-12 the opti-
mal adjunctive pharmacological
regimen to support the invasive
approach in ACS would ideally sup-
press adverse ischemic and throm-
botic events while minimizing iatro-
genic bleeding.
Author Affiliations andACUITY Investigators are listed
at the end of this article.
Corresponding Author: Gregg W. Stone, MD, Car-
diovascular Research Foundation, Columbia Univer-
sity Medical Center, 111 E 59th St, 11th Floor, New
York, NY 10022 (gs2184@columbia.edu).
Context At 30-day follow-up, patients with moderate- and high-risk acute coronary
syndromes (ACS) undergoing early invasive treatment in the ACUITY trial with bivaliru-
dinmonotherapy vs heparin plus glycoprotein (GP) IIb/IIIa inhibitors had noninferior rates
of adverse ischemic events with reduced rates of major bleeding. Deferred upstream use
of GP IIb/IIIa inhibitors for selective administration to patients undergoing percutaneous
coronary intervention (PCI) resulted in a significant reduction in major bleeding, al-
though a small increase in composite ischemia could not be excluded.
Objective To determine 1-year ischemic outcomes for patients in the ACUITY trial.
Design, Setting, and Patients A prospective, randomized, open-label trial with
1-year clinical follow-up at 450 academic and community-based institutions in 17 coun-
tries. A total of 13 819 patients with moderate- and high-risk ACS undergoing inva-
sive treatment were enrolled between August 23, 2003, and December 5, 2005.
Interventions Patients were assigned to heparin plus GP IIb/IIIa inhibitors (n=4603),
bivalirudin plus GP IIb/IIIa inhibitors (n=4604), or bivalirudin monotherapy (n=4612).
Of these patients, 4605 were assigned to routine upstream GP IIb/IIIa administration
and 4602 were deferred to selective GP IIb/IIIa inhibitor administration.
MainOutcomeMeasure Composite ischemia (death, myocardial infarction, or un-
planned revascularization for ischemia) at 1 year.
Results Composite ischemia at 1 year occurred in 15.4% of patients assigned to hep-
arin plus GP IIb/IIIa inhibitors and 16.0% assigned to bivalirudin plus GP IIb/IIIa in-
hibitors (compared with heparin plus GP IIb/IIIa inhibitors, HR, 1.05; 95% CI, 0.95-
1.16; P=.35), and 16.2% assigned to bivalirudin monotherapy (HR, 1.06; 95% CI,
0.95-1.17; P=.29). Mortality at 1 year occurred in an estimated 3.9% of patients as-
signed to heparin plus GP IIb/IIIa inhibitors, 3.9% assigned to bivalirudin plus GP IIb/
IIIa inhibitors (HR, 0.99; 95% CI, 0.80-1.22; P=.92), and 3.8% assigned to bivaliru-
dinmonotherapy (HR, 0.96; 95%CI, 0.77-1.18; P=.67). Composite ischemia occurred
in 16.3% of patients assigned to deferred use compared with 15.2% of patients as-
signed to upstream administration (HR, 1.08; 95% CI, 0.97-1.20; P=.15).
Conclusions At1 year, no statistically significant difference in rates of composite ische-
mia or mortality among patients with moderate- and high-risk ACS undergoing invasive
treatmentwith the 3 therapieswas found. Therewas no statistically significant difference
in the rates of composite ischemia between patients receiving routine upstream admin-
istration of GP IIb/IIIa inhibitors vs deferring their use for patients undergoing PCI.
Trial Registration clinicaltrials.gov Identifier: NCT00093158
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In the large-scale, prospective Acute
Catheterization and Urgent Interven-
tion Triage Strategy (ACUITY) trial,
randomization of moderate-risk and
high-risk patients with ACS undergo-
ing early invasive management to
monotherapy with the direct throm-
bin inhibitor bivalirudin comparedwith
a heparin-based regimen plus glyco-
protein (GP) IIb/IIIa inhibitors re-
sulted in noninferior 30-day rates of
composite ischemia (7.8% vs 7.3%, re-
spectively; P=.32; relative risk [RR],
1.08; 95% confidence interval [CI],
0.93-1.24) and significantly reduced
major bleeding (3.0% vs 5.7%, respec-
tively; P .001; RR, 0.53; 95%CI, 0.43-
0.65).13 In addition, in a separate ran-
domization of the patients assigned to
GP IIb/IIIa inhibitors, deferring the rou-
tine upstream use of GP IIb/IIIa inhibi-
tors for selective administration in the
catheterization laboratory only to pa-
tients undergoing PCIwas found in this
trial to result in a significant reduc-
tion inmajor bleeding at 30 days (4.9%
vs 6.1%, respectively; P=.009; RR, 0.80;
95% CI, 0.67-0.95), although a small
increase in composite ischemia could
not be excluded (7.9% vs 7.1%, respec-
tively; P=.13; RR, 1.12; 95% CI, 0.97-
1.29).14
The long-term effect of bivalirudin
monotherapy and a deferred selective
GP IIb/IIIa inhibitor utilization strat-
egy on composite ischemia and mor-
tality are unknown. This issue is
particularly relevant given the slightly
higher point estimates for com-
posite ischemia at 30 days with
these 2 therapies compared with the
control therapy. Our study therefore
describes the 1-year clinical outcomes
of patients enrolled in the ACUITY
trial.
METHODS
Patient Population
The ACUITY trial protocol has been
previously described in detail.15 In
summary, patients older than 18 years
with symptoms of unstable angina
lasting for at least 10 minutes within
the preceding 24 hours were eligible
for enrollment if 1 or more of the fol-
lowing criteria were met: (1) new
ST-segment depression or transient
elevation of at least 1 mm, (2) tropo-
nin I or T or creatine kinase–MB
elevation, (3) known coronary artery
disease, or (4) all 4 other Thromboly-
sis in Myocardial Infarction (TIMI)
unstable angina risk criteria16 positive.
Major exclusion criteria included
acute ST-segment elevation MI or
shock; bleeding diathesis or major
bleed within 2 weeks; thrombocyto-
penia; calculated creatinine clearance
level of less than 30 mL/min (to con-
vert to mL/s, multiply by 0.0167);
current warfarin use; administration
of abciximab or fibrinolytic therapy
within 24 hours of randomization,
bivalirudin within 6 hours, 2 or more
doses of low-molecular-weight hepa-
rin, or any fondaparinux use for the
present admission; or allergy to study
drugs or iodinated contrast that could
not be premedicated. The study was
approved by the institutional review
board or ethics committee at each
participating center, and all patients
signed written informed consent.
Randomization and Study Protocol
Telephone randomization was per-
formed using an interactive voice
response system in blocks of 6 strati-
fied by site and by the use or intent to
administer a thienopyridine before
angiography. Patients were equally
assigned to the open-label use of 1 of
3 antithrombin regimens begun
before angiography: heparin (either
unfractionated or enoxaparin at site
discretion) plus GP IIb/IIIa inhibitors,
bivalirudin plus GP IIb/IIIa inhibitors,
or bivalirudin alone (FIGURE 1). The
antithrombin dosing regimens have
been previously described.15
Patients assigned to heparin plus
GP IIb/IIIa inhibitors or bivalirudin
plus GP IIb/IIIa inhibitors were ran-
domized again in a 22 factorial
design to routine upstream GP IIb/IIIa
inhibitor initiation in all patients
immediately after randomization vs
deferred selective GP IIb/IIIa inhibitor
initiation in the catheterization labo-
ratory only after diagnostic angiogra-
phy identified which patients would
undergo immediate PCI (Figure 1).
Per the American College of Car-
diology/American Heart Association
and European Society of Cardiology
guidelines, either eptifibatide or tiro-
fiban were permitted for upstream
use in ACS, and either double-bolus
epti f ibatide or abciximab were
allowed for initiation in the catheter-
ization laboratory before PCI.16,17 Pro-
visional GP IIb/IIIa inhibitor use was
permitted before angiography in
patients randomized to deferred GP
IIb/IIIa inhibitor use for severe break-
through ischemia, and in patients
receiving bivalirudin monotherapy for
protocol-specified thrombotic compli-
cations occurring during PCI. Details
of the antithrombin and GP IIb/IIIa
inhibitor dosing regimens have been
previously described.15
Angiographywas performed in all pa-
tients within 72 hours after random-
ization, after which treatment was by
PCI, coronary artery bypass graft
(CABG) surgery, or medication per
physician discretion. Aspirin was ad-
ministered either orally at 300 to 325
mg/d or intravenously at 250 to 500
mg/d during the index hospitaliza-
tion, and 75 to 325 mg/d was pre-
scribed indefinitely after discharge. The
initial dosing and timing of clopido-
grel were left to investigator discre-
tion per local standards, although a 300
mg or more loading dose was required
in all cases within 2 hours after PCI.
Clopidogrel (75 mg/d) was recom-
mended for 1 year in all patients with
coronary artery disease.
Clinical End Points
and Statistical Methods
Clinical end points were assessed at 30
days (permitted follow-up range, 25-35
days) and at 1 year (permitted fol-
low-up range, 335-395 days). As pre-
viously described,13,14 the primary 30-
day end points of the trial included
composite ischemia (death from any
cause, MI, or unplanned revasculariza-
tion for ischemia), major bleeding not
related to CABG surgery, and net clini-
cal outcomes (composite ischemia or
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major bleeding). Only composite is-
chemic end points were systemati-
cally evaluated after 30 days and com-
prise the basis of our study. A clinical
events committee blinded to treat-
ment assignment adjudicated all 30-
day and1-year primary endpoint events
using original source documents.
Follow-up analysis was performed
by using time-to-event data (for which
patients were censored at the time of
withdrawal from the study or at last
follow-up), are displayed usingKaplan-
Meier methodology, and were com-
paredwith the log-rank test. The 1-year
end point was prespecified to be deter-
mined at 365 days. Although follow-
up between 365 days and 395 days was
obtained in some patients, the Kaplan-
Meier curves are truncated at exactly
365 days because of rapid decline in
the number patients at risk after 1 year.
All follow-up data and any known
events to 395 days were used in the cal-
culation of hazard ratios (HRs) andCIs
so as to not exclude the contribution
of any known adverse events. Because
the baseline features between random-
ized treatment groups were well-
matched, multivariate adjustment was
not required.
The ACUITY trial was designed as a
sequential noninferiority and superior-
ity trial for the primary end points at
30 days, with noninferiority powered
using a 25% relative margin.13 ,14
This study represents a prespecified
analysis of 1-year events from the
ACUITY trial. However, no formal
noninferiority margin was prespecified
at 1 year. The effects of treatment
assignment on the occurrence of com-
posite ischemia and mortality were
tested in multiple subgroups (all of
which were prespecified except for
United States vs non-US enrollment
site), with formal interaction testing to
determine whether differential effects
of treatment assignment were present
across the subgroup strata. All
statistical analyses were performed by
using SAS version 8.2 (SAS Institute
Inc, Cary, North Carolina) and Stata
version 9.2 (StataCorp, College Sta-
tion, Texas).
RESULTS
Patients
Between August 23, 2003, and Decem-
ber 5, 2005, 13 819 patients with ACS
were enrolled at 450 academic and com-
munity-based centers in 17 countries
and randomized to heparin (unfrac-
tionated or enoxaparin) plus GP IIb/
IIIa inhibitors (n=4603), bivalirudin
plus GP IIb/IIIa inhibitors (n=4604),
or bivalirudinmonotherapy (n=4612)
(Figure 1). Of 9207 patients random-
ized to receive GP IIb/IIIa inhibitors,
4605 and 4602 patients were assigned
to either routine upstream or deferred
selective GP IIb/IIIa inhibitor admin-
Figure 1. Randomization Flow and Follow-up of the ACUITY Trial
4603 Randomized to receive 
unfractionated heparin or 
enoxaparin + glycoprotein 
IIb/IIIa inhibitor
2294 Randomized to receive 
upstream routine 
glycoprotein IIb/IIIa
inhibitor initiation
2254 Completed follow-up at 
365 (range, 335-395) d
4603 Included in analysis 4604 Included in analysis 4612 Included in analysis
2269 Completed follow-up at 
365 (range, 335-395) d
2259 Completed follow-up at 
365 (range, 335-395) d
2245 Completed follow-up at 
365 (range, 335-395) d
9 Withdrew consent
31 Lost to follow-up
7 Withdrew consent
33 Lost to follow-up
12 Withdrew consent
40 Lost to follow-up
12 Withdrew consent
36 Lost to follow-up
22 Withdrew consent
73 Lost to follow-up
2309 Randomized to receive 
deferred selective 
glycoprotein IIb/IIIa
inhibitor initiation in the
catheterization laboratory
2311 Randomized to receive 
upstream routine 
glycoprotein IIb/IIIa
inhibitor initiation
2293 Randomized to receive 
deferred selective 
glycoprotein IIb/IIIa
inhibitor initiation in the
catheterization laboratory
4604 Randomized to receive 
bivalirudin + glycoprotein 
IIb/IIIa inhibitor
4612 Randomized to receive 
bivalirudin monotherapy
13 819 Patients with moderate-risk 
and high-risk acute coronary
syndromes randomized
4603 Randomized 4604 Randomized
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy. Clinical end points were assessed at 365 days (permitted follow-up range, 335-395
days). Patients who withdrew consent are censored at the time of last follow-up.
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istration, respectively. One-year fol-
low-up was completed in 13 544 pa-
tients (98.0%). Selected baseline
characteristics and medication use are
shown in TABLE 1 and were well bal-
anced between the 3 primary groups.
Angiography was performed at a me-
dian time of 19.6 hours after admis-
sion (mean, 23.9 hours), following
treatment by PCI in 7789 patients
(56.4%), CABG surgery in 1539 pa-
tients (11.1%), andmedical therapy in
4491 patients (32.5%). Compliance
with aspirin was high throughout the
1-year period, whereas thienopyri-
dine usage was less frequent between
the 30-day and 1-year follow-up peri-
ods.
One-Year Clinical Outcomes
Compared with the control group of
heparin plus GP IIb/IIIa inhibitors in
which the 1-year estimated rate of com-
posite ischemia was 15.4%, composite
ischemia occurred in 16.0% of pa-
tients assigned to bivalirudin plus GP
IIb/IIIa inhibitors (HR, 1.05; 95% CI,
0.95-1.16; P=.35) and in 16.2% of pa-
tients assigned to bivalirudin mono-
therapy (HR, 1.06; 95% CI, 0.95-1.17;
P=.29) (TABLE 2 and FIGURE 2). There
were no significant differences in the
rates of the individual components of
death,MI, or unplanned revasculariza-
tion for ischemia between the 3 groups
(Table 2). A total of 524 patients died
within 1 year (range, 335-395 days) of
randomization, including 178, 176, and
170 patients in the heparin plusGP IIb/
Table 1. Selected Baseline Characteristics, Medication Use, and Treatments of the Study
Populationa
Characteristics
Heparin  GP
IIb/IIIa Inhibitors
(n = 4603)
Bivalirudin  GP
IIb/IIIa Inhibitors
(n = 4604)
Bivalirudin
Monotherapy
(n = 4612)
Baseline features
Age, mean (SD), y 62.7 (11.5) 62.5 (11.9) 62.5 (11.6)
Male sex 3249/4603 (70.6) 3218/4604 (69.9) 3195/4612 (69.3)
Diabetes 1298/4564 (28.4) 1267/4568 (27.7) 1287/4577 (28.1)
Hypertension 3058/4577 (66.8) 3074/4577 (67.2) 3080/4593 (67.1)
Hyperlipidemia 2580/4511 (57.2) 2588/4508 (57.4) 2579/4521 (57.0)
Current smoker 1308/4508 (29.0) 1323/4522 (29.3) 1312/4527 (29.0)
Prior myocardial infarction 1419/4493 (31.6) 1372/4491 (30.5) 1431/4499 (31.8)
Renal insufficiencyb 826/4298 (19.2) 824/4302 (19.2) 819/4339 (18.9)
Baseline troponin or creatine
kinase MB elevation
2503/4213 (59.4) 2479/4236 (58.5) 2570/4263 (60.3)
Baseline troponin elevation 2290/3931 (58.3) 2276/3980 (57.2) 2349/3971 (59.2)
Baseline ST-segment
deviation 1 mm
1618/4598 (35.2) 1628/4599 (35.4) 1579/4607 (34.3)
Treatment strategy
PCI 2561/4603 (55.6) 2609/4604 (56.7) 2619/4612 (56.8)
CABG surgery 549/4603 (11.9) 499/4604 (10.8) 491/4612 (10.6)
Medical therapy 1493/4603 (32.4) 1496/4604 (32.5) 1502/4612 (32.6)
Antiplatelet medication use
Aspirin
Before angiography
or intervention
4446/4535 (98.0) 4427/4528 (97.8) 4442/4536 (97.9)
At hospital discharge 3787/4419 (85.7) 3779/4391 (86.1) 3764/4392 (85.7)
30-d follow-upc 4141/4470 (92.6) 4124/4442 (92.8) 4142/4451 (93.1)
1-y follow-upc 3789/4324 (87.6) 3816/4321 (88.3) 3830/4349 (88.1)
In patients with PCI onlyc 2235/2428 (92.1) 2259/2472 (91.4) 2312/2503 (92.4)
Thienopyridine
Before angiography
or intervention
2842/4526 (62.8) 2924/4520 (64.7) 2911/4532 (64.2)
At hospital discharge 2872/4419 (65.0) 2891/4391 (65.8) 2905/4392 (66.1)
30-d follow-upc 2979/4470 (66.6) 3050/4442 (68.7) 3055/4451 (68.6)
1-y follow-upc 1936/4324 (44.8) 1918/4321 (44.4) 1922/4349 (44.2)
In patients with PCI onlyc 1400/2428 (57.7) 1392/2472 (56.3) 1377/2503 (55.0)
Abbreviations: CABG, coronary artery bypass graft; GP, glycoprotein; PCI, percutaneous coronary intervention.
aHeparin indicates unfractionated heparin or enoxaparin at site discretion. Data are expressed as No./total No. (%)
unless otherwise indicated. The total denominators for each treatment are represented at the top of each group
column; for each cell, the specific denominator with available data is provided. Because of rounding, percentages
may not total 100.
bCreatinine clearance calculated as less than 60 mL/min using the Cockcroft-Gault equation (to convert to mL/s, mul-
tiply by 0.0167).
cTaken on more than 50% of days since last visit.
Table 2. Clinical Outcomes at 1 Year According to Antithrombin Randomizationa
Heparin  GP
IIb/IIIa Inhibitors
(n = 4603)b
Bivalirudin  GP
IIb/IIIa Inhibitors
(n = 4604)b
Hazard Ratio
(95% CI)c
P
Valuec
Bivalirudin
Monotherapy
(n = 4612)b
Hazard Ratio
(95% CI)d
P
Valued
Composite ischemia 15.4 (693) 16.0 (723) 1.05 (0.95-1.16) .35 16.2 (731) 1.06 (0.95-1.17) .29
Death from any cause 3.9 (172) 3.9 (173) 0.99 (0.80-1.22) .92 3.8 (169) 0.96 (0.77-1.18) .67
Myocardial infarction 6.9 (310) 7.1 (320) 1.03 (0.88-1.21) .68 7.8 (349) 1.13 (0.97-1.32) .11
Q-wave 1.5 (69) 1.3 (60) 0.85 (0.60-1.19) .34 1.5 (67) 0.96 (0.69-1.34) .80
Non–Q-wave 5.4 (244) 5.9 (264) 1.09 (0.92-1.30) .32 6.4 (286) 1.18 (0.99-1.40) .054
Unplanned revascularization
for ischemia
8.4 (368) 9.1 (400) 1.10 (0.96-1.27) .16 8.7 (385) 1.05 (0.91-1.21) .49
Abbreviations: CI, confidence interval; GP, glycoprotein.
aHeparin indicates unfractionated heparin or enoxaparin at site discretion.
bPercentages are expressed as Kaplan-Meier estimates (No. of events) at exactly 365 days.
cFor comparison of bivalirudin plus GP IIb/IIIa inhibitors vs heparin plus GP IIb/IIIa inhibitors.
dFor comparison of bivalirudin monotherapy vs heparin plus GP IIb/IIIa inhibitors.
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IIIa inhibitor, bivalirudin plus GP IIb/
IIIa inhibitor, and bivalirudin mono-
therapy groups, respectively.Within the
first 30 days after randomization, 64,
71, and 74 patients died in the 3 groups,
respectively. Between the end of the 30-
day and 1-year follow-up periods, 114,
105, and 96 patients died in the 3
groups, respectively. The 95%CI of the
HR comparing bivalirudin mono-
therapy to heparin plus GP IIb/IIIa in-
hibitors during the 1-year follow-up pe-
riod was 0.77 to 1.18 (Table 2). The
results comparing the 3 treatment
groups for 1-year composite ischemia
andmortality did notmaterially change
in a sensitivity analysis in which all pa-
tients lost to follow-up were assumed
to have died the day after last patient
contact.
Formal interaction testing demon-
strated that the treatment comparison
of bivalirudin monotherapy vs hepa-
rin plus GP IIb/IIIa inhibitors for
1-year composite ischemia was con-
sistent across multiple prespecified
subgroups , inc luding pat ients
biomarker-positive, those with high-
risk TIMI criteria, and those treated
with PCI. Although the point estimate
for composite ischemia at 1 year in
patients first receiving a thienopyri-
dine either after angiography or PCI,
or not at all favored heparin plus GP
IIb/IIIa inhibitors, this interaction did
not reach statistical significance
(P= .18) (FIGURE 3). Moreover, no
significant interaction between ran-
domized treatment and any sub-
group, including the timing of
thienopyridine administration, was
present with regard to 1-year mortal-
ity, and the point estimate and HR
for 1-year mortality favored bivaliru-
din monotherapy in patients in
whom a thienopyridine was adminis-
tered either before or after angiogra-
phy (FIGURE 4).
Deferred selective GP IIb/IIIa inhibi-
tor administration comparedwith rou-
tine upstream use (pooled across anti-
thrombin randomization) did not result
in statistically significant differences in
the 1-year rates of composite ischemia
(16.3% vs 15.2%; HR, 1.08; 95% CI,
0.97-1.20; P=.15) or mortality (4.0%
vs 3.8%; HR, 1.05; 95% CI, 0.85-1.29;
P=.66) (FIGURE 5).
Serious adverse events within 1 year
of randomization were reported by the
sites (but not adjudicated by central
committee) in 1439 of the 13 819
enrolled patients (10.4%). The most
common adverse events included car-
diac disorders (552 [4.0%]), general
disorders including administration site
(280 [2.0%]), infections (182 [1.3%]),
respiratory disorders (164 [1.2%]),
vascular disorders (126 [0.9%]), ner-
vous system disorders (121 [0.9%]),
and gastrointestinal disorders (81
[0.6%]). Any serious adverse event
was reported in 491 patients assigned
to heparin plus GP IIb/IIIa inhibitors
(10.7%), in 455 patients assigned to
bivalirudin plus GP IIb/IIIa inhibitors
(9.9%), and in 493 patients assigned
Figure 2. Kaplan-Meier Estimates Comparing Patients Randomized to Heparin
(Unfractionated or Enoxaparin) Plus Glycoprotein (GP) IIb/IIIa Inhibitors, Bivalirudin Plus GP
IIb/IIIa Inhibitors, and Bivalirudin Monotherapy for Composite Ischemia and Mortality
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Y-axis shown in blue indicates range of 0% to 5%. Compared with the control group of heparin (unfraction-
ated or enoxaparin) plus GP IIb/IIIa inhibitors, no statistically significant difference was found in the rates of
composite ischemia from bivalirudin plus GP IIb/IIIa inhibitors (log-rank P=.35) or bivalirudin monotherapy
(log-rank P=.29), or in the rates of mortality from bivalirudin plus GP IIb/IIIa inhibitors (log-rank P=.92) or
bivalirudin monotherapy (log-rank P=.67).
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to bivalirudin monotherapy (10.7%).
There were no significant differences
among treatment groups in the occur-
rence of overall or system-specific seri-
ous adverse events.
COMMENT
Antithrombotic Strategies in ACS
Therapeutic imperatives in the early
treatment phase of patients with mod-
erate-risk and high-risk ACS include
coronary angiography followed by re-
vascularizationwhen appropriate to sta-
bilize the ruptured atherosclerotic
plaque. Evidencehas accumulateddem-
onstrating the deleterious effect of ma-
Figure 3. Subgroup Analyses Comparing Patients Randomized to Heparin Plus Glycoprotein (GP) IIb/IIIa Inhibitors and Bivalirudin
Monotherapy for the 1-year Kaplan-Meier Estimated Rates of Composite Ischemia
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jor bleeding as well as MI in patients
with ACS and in those undergoing PCI.
As such, the optimal pharmacological
regimen to support an early invasive
strategy in ACS would ideally sup-
press adverse ischemic and throm-
botic events before and during inter-
vention while minimizing iatrogenic
hemorrhagic complications.
We previously reported 30-day re-
sults from the ACUITY trial. In pa-
tients with moderate-risk and high-
risk ACS undergoing an early invasive
strategy comparedwith treatment with
heparin plus GP IIb/IIIa inhibitors, bi-
valirudin bothwith andwithoutGP IIb/
IIIa inhibitors was noninferior with re-
spect to composite ischemia, and
Figure 4. Subgroup Analyses Comparing Patients Randomized to Heparin Plus Glycoprotein (GP) IIb/IIIa Inhibitors and Bivalirudin
Monotherapy for the 1-year Kaplan-Meier Estimated Rates of Mortality
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bivalirudin monotherapy was associ-
ated with decreased rates of bleed-
ing.13 We also reported that deferring
the routine upstream use of GP IIb/
IIIa inhibitors for selective administra-
tion in the catheterization laboratory
only to patients undergoing PCI re-
sulted in a significant reduction inma-
jor bleeding at 30 days, although a small
increase in composite ischemia could
not be excluded.
After hospital discharge, therapeu-
tic success in patients with ACS ismea-
sured in terms of long-term survival and
freedom from recurrent ischemia. Our
1-year results provide information that
helps to address this issue. At 30 days,
treatment with heparin plus GP IIb/
IIIa inhibitors, bivalirudinwith GP IIb/
IIIa inhibitors, and bivalirudin mono-
therapy resulted in composite ischemia
rates of 7.4%, 7.9%, and 8.0%, respec-
tively.13 Between the 30-day and 1-year
follow-up periods, the absolute differ-
ences in composite ischemia between
the 3 groups remained roughly paral-
lel such that the event rates at the end
of the follow-up period were not sig-
nificantly different (15.4%, 16.0%, and
16.2%, respectively). The 1-year up-
per bound of the 95% CIs of the HRs
for bivalirudin with or without GP IIb/
IIIa inhibitors compared with heparin
plusGP IIb/IIIa inhibitors was 1.16 and
1.17, respectively. These observed rates
are consistent with what has been sug-
gested as acceptable for clinical thera-
peutic interchangeability (relative dif-
ference 20%).18
Despite high compliance with all
protocol mandated class I guideline
therapies, including early revascular-
ization,16,17 mortality by the end of the
1-year follow-up period occurred in
524 patients, with approximately 60%
of the deaths occurring after 30 days,
reflecting the high-risk nature of the
study cohort. Mortality between the
end o f the 30-day and 1-yea r
follow-up periods occurred in 114,
105, and 96 patients assigned to hepa-
rin plus GP IIb/IIIa inhibitors, bivali-
rudin plus GP IIb/IIIa inhibitors, and
bivalirudin monotherapy, respectively,
with the curves crossing at approxi-
mately 6 months. As a result, mortality
at 365 days occurred in an estimated
3.9%, 3.9%, and 3.8% of patients,
respectively. The HR for 1-year mor-
tality comparing bivalirudin mono-
therapy to heparin plus GP IIb/IIIa
inhibitors was 0.96 (95% CI, 0.77-
1.18), with an upper bound of 18%
higher mortality, also consistent with
clinical therapeutic interchangeability.
The observation that the rate of
1-year mortality for bivalirudinmono-
therapy was not statistically signifi-
cantly different from heparin plus GP
IIb/IIIa inhibitors may reflect the op-
posing effects of the risk of MI11,12,19
(point estimate slightly but nonsignifi-
cantly greater in the bivalirudinmono-
therapy group) and the risk of major
bleeding within 30 days3-10 (signifi-
cantly reduced in the bivalirudinmono-
therapy group) on subsequent mortal-
ity.20 Further studies are required to
determine whether the prevention of
major bleeding directly prolongs sur-
vival and, if this were found, to eluci-
date the mechanisms underlying such
a beneficial effect.
Subgroup Analysis
Formal interaction testing among pa-
tients randomized to bivalirudinmono-
therapy vs heparin plus GP IIb/IIIa
inhibitors revealed no treatment dif-
ferences related to multiple baseline
demographic and procedural vari-
Figure 5. Kaplan-Meier Estimates Comparing Routine Upstream Glycoprotein (GP) IIb/IIIa
Inhibitor Administration and Deferred Selective GP IIb/IIIa Inhibitor Administration for
Composite Ischemia and Mortality
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ables for the occurrence of composite
ischemia at 1 year. Although compos-
ite ischemia by 1 year tended to occur
more frequently in patients random-
ized to bivalirudin monotherapy if a
thienopyridine was not administered
before angiography or PCI, this inter-
action was not statistically significant
(P=.18). Moreover, the point estimate
for mortality at 1 year favored bivali-
rudinmonotherapy in patients inwhom
a thienopyridine was administered
either before or after angiography.Mor-
tality rates at 1 year were also compa-
rable in other subgroups of patients
treated with bivalirudin monotherapy
compared with heparin plus GP IIb/
IIIa inhibitors, including those with in-
creased baseline troponin or creatine ki-
nase MB levels, ST-segment deviation,
high TIMI unstable angina risk score,
advanced age, and renal insufficiency.
GP IIb/IIIa Inhibitor
Administration Strategies
Deferred selective GP IIb/IIIa inhibi-
tor use compared with routine up-
stream GP IIb/IIIa inhibitor adminis-
tration resulted in a nonsignificant
slightly greater point estimate for 1-year
composite ischemia, with the upper
bound of the 95% CI of the HR being
1.20. The observed rates ofmortality at
1 year were nearly identical with these
2 strategies (4.0% and 3.8%, respec-
tively), despite nonsignificant but nu-
merical increases in the occurrence of
MI and unplanned revascularization for
ischemia with the selective approach.
This observation might be due to the
reduction in 30-day bleeding with the
deferred selective use of GP IIb/IIIa in-
hibitors compared with their routine
upstream administration.14
Study Strengths and Limitations
The ACUITY trial was designed and
powered to evaluate sequential nonin-
feriority and superiority between the 3
antithrombin regimens and the 2 gly-
coprotein utilization strategies for the
30-day composite end points of com-
posite ischemia,major bleeding, andnet
clinical outcomes. Formal noninferi-
ority or superiority hypotheseswere not
prespecified for 1 year and the power
for the 1-year analysis was not prospec-
tively determined. As such, the results
of our study should be considered ex-
ploratory and hypothesis generating.
Nonetheless, with relatively highmor-
tality in this large prospective study and
with 1-year follow-up achieved in 98%
of patients, large differences in the
1-year rates of composite ischemia and
mortality between bivalirudin mono-
therapy and heparin plusGP IIb/IIIa in-
hibitors, and in composite ischemia be-
tween the differentGP IIb/IIIa inhibitor
utilization strategies, are unlikely.
Our study did not have optimal
power for robust superiority or nonin-
feriority testing among the sub-
groups, the results of which should also
be considered hypothesis generating,
especially given noncorrection formul-
tiple comparisons.21 In addition, inter-
action testing is inherently underpow-
ered and we cannot exclude that
significant differencesmay exist in some
of the subgroups, especially those in
which the HRs vary moderately be-
tween groups. Further study is also re-
quired to determine the optimal anti-
thrombotic and antiplatelet regimens in
patients with ACS excluded from ran-
domization, such as those with severe
renal insufficiency or in patients treated
conservatively without early invasive
treatment.
Other limitations of theACUITY trial
have been previously discussed and ap-
ply to this study.13,14 In brief, the logis-
tic complexities of the trial necessi-
tated an open-label design,mitigated by
adjudication of all primary clinical end
point events through 1 year by an in-
dependent committee blinded to treat-
ment assignment and requiring origi-
nal source documents for confirmation.
To reflect current practice, the selec-
tion of unfractionatedheparin vs enoxa-
parin and the choice of eptifibatide vs
tirofiban for upstream use or eptifi-
batide vs abciximab for catheteriza-
tion laboratory initiation were left to
physician discretion, given the lack of
randomized studies demonstrating
clinically important differences in out-
comes between these agents for their in-
dicated uses.22 Further study, includ-
ing propensity adjustment for the
selection of one agent vs another, is re-
quired to exclude any possible effect of
this pooling on the study conclusions.
Analysis regarding the impact of dos-
ing errors and protocol nonadherence
in the treatment and control groups also
has not yet been completed.
Crossover from prerandomization
heparin to bivalirudinwas commonand
may have adversely affected the re-
sults among patients treated with bi-
valirudin. Given the heterogeneous na-
ture of the patients enrolled and
therapies received, including the deci-
sion whether to administer clopido-
grel before angiography, varying choice
of antithrombin and antiplatelet agents,
and treatment of patients following an-
giography with either PCI, CABG, or
medical therapy (the thresholds for
which vary between physicians), de-
finitive conclusions cannot bemade re-
garding the relative safety and efficacy
of the assigned treatments in all sce-
narios.
CONCLUSIONS
At 1-year follow-upof theACUITY trial,
therewas no statistically significant dif-
ference in rates of composite ischemia
ormortality among patients withmod-
erate-risk and high-risk ACS undergo-
ing invasive treatmentwithheparin plus
GP IIb/IIIa inhibitors, bivalirudin plus
GP IIb/IIIa inhibitors, or bivalirudin
monotherapy. There was no statisti-
cally significant difference in rates of
composite ischemia between patients
receiving routine upstream adminis-
tration of GP IIb/IIIa inhibitors vs de-
ferring their use for patients undergo-
ing PCI.
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